Patent: 5,844,095
✉ Email this page to a colleague
Summary for Patent: 5,844,095
| Title: | CTLA4 Ig fusion proteins |
| Abstract: | The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins, and for using the soluble fusion proteins, fragments and derivatives thereof, including monoclonal antibodies reactive with B7 and CTLA4, to regulate T cell interactions and immune responses mediated by such interactions. |
| Inventor(s): | Peter S. Linsley, Jeffrey A. Ledbetter, Nitin K. Damle, William Brady |
| Assignee: | Bristol Myers Squibb Co |
| Application Number: | US08/375,390 |
| Patent Claims: | see list of patent claims |
Details for Patent 5,844,095
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Bristol-myers Squibb Company | ORENCIA | abatacept | For Injection | 125118 | December 23, 2005 | 5,844,095 | 2015-12-01 |
| Bristol-myers Squibb Company | ORENCIA | abatacept | Injection | 125118 | July 29, 2011 | 5,844,095 | 2015-12-01 |
| Bristol-myers Squibb Company | ORENCIA | abatacept | Injection | 125118 | June 07, 2016 | 5,844,095 | 2015-12-01 |
| Bristol-myers Squibb Company | ORENCIA | abatacept | Injection | 125118 | March 30, 2017 | 5,844,095 | 2015-12-01 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
